The upcoming earnings report for Sarepta Therapeutics is scheduled for Tuesday, May 5th. Analysts estimate an earnings per share of $0.976.
Sarepta Therapeutics' current price stands at $21.24, reflecting a price change of 26.31 cents, with a percentage change of 1.25%. The trading volume is $805,639, which is 28.52% higher than the average.
Sarepta Therapeutics' latest quarterly earnings report, dated Tuesday, February 24th, showed a consensus estimate EPS of -0.71.
The company's free cash flow is $125.38 million, with net cash increasing by $188.21 million. Operating cash flow is $131.21 million, and debt repayment amounted to $35.13 million.
Sarepta Therapeutics reported a revenue of $442.93 million, with gross profit at $44.23 million. The net income was -$282.85 million, resulting in an EPS of -$2.74.
Key financial ratios include a quick ratio of 1.48, gross profit margin of 10%, and return on equity at -24.8%.
The balance sheet shows total assets of $3.35 billion, total liabilities of $2.21 billion, and a net debt of $238.27 million.
This comprehensive financial report provides insights into Sarepta Therapeutics' earnings expectations, performance, and financial health.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.